Darzalex 100 mg Injection
Brand Name: Darzalex
Molecule: Daratumumab
Strength: 100 mg
Quantity: 1 vial
Form: Injection
Packaging Type: vial
Manufacturer/Marketed By: Janssen Pharmaceuticals
Country of Origin: Belgium
Please fill in the details below, and we’ll get back to you as soon as possible
No similar products found.
Description
Darzalex 100 mg Injection contains daratumumab, a monoclonal antibody medicine used in the treatment of certain blood cancers, particularly multiple myeloma. It belongs to a class of medicines known as CD38-directed cytolytic antibodies, which target specific proteins found on the surface of cancerous plasma cells. By binding to these proteins, daratumumab helps the immune system identify and destroy malignant cells when used as prescribed by a qualified healthcare professional. Darzalex is typically administered as an intravenous infusion in a clinical setting by trained healthcare providers. It may be used alone or in combination with other anticancer medicines depending on the stage of disease and treatment plan recommended by an oncologist. Patients receiving this treatment are usually monitored through regular laboratory tests and medical evaluations to assess response and manage po
Benefits
-
Targets CD38 proteins found on multiple myeloma cells
-
Helps the immune system recognize and destroy malignant plasma cells
-
Used in combination therapy regimens for multiple myeloma
-
Administered under medical supervision in specialized oncology settings
-
Part of modern immunotherapy approaches in hematologic cancers
Indications and Usage
Darzalex (daratumumab) may be prescribed for adults with:
-
Multiple myeloma, including newly diagnosed cases in certain treatment regimens
-
Relapsed or refractory multiple myeloma
-
Use in combination with other anticancer medicines such as lenalidomide, bortezomib, dexamethasone, or pomalidomide depending on clinical protocols
Treatment decisions are based on disease stage, prior therapies, and patient health status.
How it Works
Daratumumab works by targeting CD38, a protein highly expressed on the surface of multiple myeloma cells. By binding to this protein, the medicine activates several immune-mediated mechanisms that help destroy cancer cells. These mechanisms include antibody-dependent cellular cytotoxicity, complement activation, and immune cell–mediated destruction.
In addition to directly targeting tumor cells, daratumumab may also influence immune system activity by affecting certain immune cell populations. This targeted immunotherapy approach helps the immune system recognize and eliminate malignant plasma cells when the medicine is administered as prescribed and monitored by an oncology specialist.
Dosage & Administration
-
Darzalex is administered as an intravenous infusion in a hospital or oncology clinic.
-
Infusions are given according to a treatment schedule determined by the oncologist.
-
Initial infusions may take several hours and are administered under medical supervision.
-
Premedications may be used to reduce the risk of infusion-related reactions.
-
Treatment duration depends on clinical response, tolerance, and treatment protocol.
Side Effects
Common side effects
-
Infusion-related reactions
-
Fatigue
-
Nausea
-
Diarrhea or constipation
-
Upper respiratory infections
-
Decreased blood cell counts
Serious side effects
-
Severe infusion reactions
-
Low white blood cell counts increasing infection risk
-
Severe infections
-
Anemia or thrombocytopenia
-
Interference with certain blood compatibility tests
Patients should seek medical attention if severe symptoms occur.
Warning and Precaution
-
Risk of infusion-related reactions, particularly during the first infusion
-
Possible low blood cell counts, requiring regular monitoring
-
Increased risk of infections
-
May interfere with blood compatibility testing (cross-matching)
-
Inform healthcare providers before blood transfusions
-
Pregnancy and breastfeeding considerations should be discussed with a healthcare professional
-
Patients should inform doctors about all medications and supplements they are taking
Patient Guidance
-
Treatment will be administered by healthcare professionals in a clinical setting
-
Attend all scheduled infusion sessions and follow-up appointments
-
Report symptoms such as fever, breathing difficulty, or unusual fatigue
-
Inform healthcare providers if you require blood transfusions
-
Maintain good hygiene and infection precautions during treatment
-
Follow medical advice regarding monitoring tests and supportive care
Clinical Trial & Approvals
Daratumumab has been studied extensively in clinical trials for multiple myeloma. Studies such as the POLLUX, CASTOR, and MAIA trials demonstrated improved treatment outcomes when daratumumab was used in combination with other therapies. Based on these findings, daratumumab has received regulatory approvals from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for several multiple myeloma treatment indications.
References
-
U.S. Food and Drug Administration (FDA) – Darzalex Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761036s041lbl.pdf -
European Medicines Agency (EMA) – Darzalex (daratumumab) Product Information
https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex -
National Cancer Institute – Daratumumab Drug Information
https://www.cancer.gov -
Drugs.com – Darzalex Drug Information
https://www.drugs.com/darzalex.html -
ClinicalTrials.gov – Daratumumab Clinical Studies
https://clinicaltrials.gov
Prescription & documentation note
Darzalex 100 mg Injection is typically supplied against a valid prescription and administered in a clinical setting. For international supply requests, patients may need to provide documentation such as a licensed physician’s prescription, medical records, and identification, depending on destination country regulations. MedsMonk may assist with documentation guidance where applicable.
FAQ
What is Darzalex 100 mg Injection used for?
It is used in the treatment of multiple myeloma, a type of blood cancer affecting plasma cells.
What is the active ingredient in Darzalex?
The active ingredient is daratumumab, a monoclonal antibody targeting CD38.
Is Darzalex chemotherapy?
Darzalex is considered immunotherapy, not traditional chemotherapy.
How is Darzalex administered?
It is given as an intravenous infusion in a hospital or oncology clinic.
Can Darzalex be used with other medicines?
Yes. It is often used in combination with other anticancer medicines as part of treatment protocols.
What monitoring is required during treatment?
Patients may require blood tests, infection monitoring, and clinical evaluation.
Is a prescription required for Darzalex?
Yes. Darzalex is a prescription-only oncology medicine administered under specialist supervision.
How should Darzalex be stored?
The medicine should be stored and handled by healthcare professionals according to manufacturer guidelines.
Related Products
Related Posts:
Bone Marrow Transplant: A Complete Guide for Patients
The realization that you or someone close to you needs a bone marrow transplant can be extremely daunting. It may
READ MORE »June 16, 2026
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.